Table 1.
Baseline characteristics of the 114 patients.
| Characteristics | Statistical value |
|---|---|
| Median age, years (range) | 53 (24–79) |
| Male gender | 102 (89.5) |
| Etiology | |
| Hepatitis B | 102 (89.5) |
| Hepatitis C | 2 (1.8) |
| Non-B, Non-C | 10 (8.8) |
| BCLC stage | |
| A | 3 (2.6) |
| B | 42 (36.8) |
| C | 69 (60.5) |
| Child-Pugh class | |
| A | 111 (97.4) |
| B | 3 (2.6) |
| Tumor number | |
| 1 | 20 (17.5) |
| 2 | 21(18.4) |
| ≥3 | 73 (64.1) |
| Maximum tumor size, mm (range) | 82 (13-216) |
| Macrovascular invasion | |
| Presence | 55 (48.3) |
| Absence | 59 (51.7) |
| Extrahepatic Metastases | |
| Presence | 23 (20.2) |
| Absence | 91 (79.8) |
| AFP (ng/mL), median (Q1, Q3) | 386 (20.5, 7130.5) |
| ≥25 | 81 (71.1) |
| DCP (mAU/mL), median (Q1, Q3) | 2833 (385, 13805) |
| ≥40 | 100 (87.7) |
| TB (μmol/L), median (Q1, Q3) | 15 (11, 20) |
| ALB (g/L), median (Q1, Q3) | 40 (37, 42) |
| ALT (U/L), median (Q1, Q3) | 37 (27, 53) |
| WBC (×109),median (Q1, Q3) | 5.26 (4.22, 6.59) |
| PLT (×109),median (Q1, Q3) | 143 (112, 213) |
| NLR, median (Q1, Q3) | 2.61 (1.94, 3.32) |
| PLR, median (Q1, Q3) | 125.66 (91.80, 163.37) |
| Prior treatment before LePD1-TACE | |
| TACE | 12 (10.5) |
| TACE-MWA | 5 (4.4) |
| TACE-lenvatinib/sorafenib | 7 (6.1) |
| TACE-MWA-lenvatinib | 2 (1.8) |
| TACE-radiotherapy/lenvatinib | 6 (5.3) |
| Treatment after LePD1-TACE | |
| Lenvatinib - PD-1 | 5 (4.4) |
| Regorafenib -TACE - PD-1 | 7 (6.1) |
| TACE- atezolizumab- bevacizumab | 2 (1.8) |
| Radiotherapy- lenvatinib - PD-1 | 4 (3.5) |
| Others | 7 (6.1) |
Values are presented as median (range) or n (%). BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; DCP, Des-gammacarboxy; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; WBC, white blood cell; PLT, platelet; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; TACE, transarterial chemoembolization; MWA, microwave ablation; PD-1, programmed death receptor-1 signaling inhibitors.